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Abstract
Background: Preclinical and early phase clinical microbicide studies have not consistently predicted the outcome of efficacy
trials. To address this gap, candidate biomarkers of microbicide pharmacodynamics and safety were evaluated in a double-
blind, placebo-controlled trial of tenofovir gel, the first microbicide to demonstrate significant protection against HIV
acquisition.
Methods: 30 women were randomized to apply a single daily dose of tenofovir or placebo gel for 14 consecutive days. Anti-
HIV activity was measured in cervicovaginal lavage (CVL) on Days 0, 3, 7, 14 and 21 by luciferase assay as a surrogate marker
of pharmacodynamics. Endogenous activity against E. coli and HSV-2 and concentrations of immune mediators were
quantified in CVL as candidate biomarkers of safety. Tenofovir levels were measured in CVL and blood.
Results: A significant increase in anti-HIV activity was detected in CVL from women who applied tenofovir gel compared to
their endogenous anti-HIV activity in genital tract secretions on Day 0 and compared to activity in CVL from women in the
placebo group. The activity correlated significantly with CVL concentration of tenofovir (r=0.6, p,0.001) and fit a sigmoid
Emax pharmacodynamic model. Anti-HIV activity in CVL from women who applied tenofovir persisted when virus was
introduced in semen, whereas endogenous anti-HIV activity decreased. Tenofovir did not trigger an inflammatory response
or induce sustained loss in endogenous antimicrobial activity or immune mediators.
Conclusions: Tenofovir gel had no deleterious impact on soluble mucosal immunity. The increased anti-HIV activity in CVL,
which persisted in the presence of semen and correlated with tenofovir concentration, is consistent with the efficacy
observed in a recent clinical trial. These results promote quantified CVL anti-HIV activity as a surrogate of tissue
pharmacodynamics and as a potential biomarker of adherence to product. This simple, feasible and inexpensive bioassay
may promote the development of models more predictive of microbicide efficacy.
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Introduction
The lack of biomarkers of efficacy and safety continues to
impede development of microbicides for the prevention of HIV.
Initial in vitro studies of PRO 2000 gel suggested promising activity
against HIV-1 and HSV-2, but the microbicide failed to provide
significant protection against infection in large-scale efficacy
studies. Studies conducted in the presence of seminal plasma
and with postcoital sampling may provide a biological rationale for
this lack of protection [1,2,3,4]. We found that 14 daily
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inflammatory response or loss in endogenous antimicrobial activity
of genital tract secretions [2]. However, while sufficient biologi-
cally active drug to inhibit HIV and HSV-2 infection was retained
in cervicovaginal lavage (CVL) collected following gel application
[1,4], the antiviral activity was markedly reduced when virus was
introduced in seminal plasma, reflecting interference by seminal
proteins with the antiviral activity of PRO 2000 [3]. Moreover, the
recovered concentration of PRO 2000 and the antiviral activity in
CVL collected following sex were significantly diminished
compared to CVL collected post-gel application in the absence
of sex [4].
Tenofovir (TFV), an acyclic nucleotide analogue developed for
the treatment of HIV, has been formulated as a 1% gel and has
advanced as an antiretroviral microbicide for prevention of HIV
acquisition. Preclinical studies demonstrated in vitro activity against
HIV and safety in cell culture, explant and animal models [5].
TFV effectively blocked transmission of SIV or SHIV in non-
human primate models when given as pre- or post-exposure
prophylaxis systemically or when applied as an intravaginal gel
[6,7]. TFV did not disrupt human epithelial cell tight junctions,
induce an inflammatory response [8], or increase the susceptibility
of mice to genital herpes following seven daily vaginal applications
of gel in preclinical safety studies [9]. These results contrast with
findings obtained from the same safety models with nonoxynol-9
and cellulose sulfate, which increased susceptibility of mice to
HSV-2 infection and disrupted tight junctions in a dual chamber
model, resulting in increased migration of HIV across an epithelial
barrier [9].
Early clinical studies support the safety and efficacy of TFV
vaginal gel. A 14-day course was well tolerated in abstinent and
sexually active HIV-negative and HIV-positive women [10]. In a
subsequent Phase II study of 200 sexually active HIV-negative
women who applied 1% TFV or placebo gel daily or up to two
hours before sex for six months, no statistically significant
differences in the development of genital symptoms or in renal
function were observed between the groups [11]. Most impor-
tantly, a recently completed Phase IIb study, CAPRISA 004,
found that 1% TFV gel was effective. In CAPRISA 004, women
were instructed to insert one dose of TFV or hydroxyethylcellulose
placebo gel within 12 hours before sex and a second dose as soon
as possible within 12 hours after sex. HIV incidence in the TFV
gel arm (n=445) was 5.6 per 100 women-years compared to 9.1
per 100 women-years in the placebo gel arm (n=444), indicating a
39% reduction in HIV infection (p=0.017) [12]. These promising
results support larger efficacy trials. The optimal dosing regimen
(daily or coitally-dependent) and delivery system (gel or ring) will
require further clinical studies. The development of predictive
biomarkers of efficacy will therefore become a critical tool for
evaluating different dosing and delivery options and for advancing
new products and combinations to clinical studies.
Building on this background, we evaluated the anti-HIV activity
of TFV and concentration of drug in CVL obtained from women
during a 14-day study of vaginal TFV gel. In contrast to PRO
2000, which acts luminally, TFV is active only after permeating
target cells, where it is phosphorylated to tenofovir diphosphate
(TFV-DP). TFV-DP has a long intracellular half-life (.95 hours),
which reflects the low permeability of charged nucleotides and low
rate of intracellular dephosphorylation [13,14]. Thus, the
pharmacodynamics (PD) of TFV gel might best be measured by
challenging vaginal or cervical tissue ex vivo with HIV. However,
the limited feasibility of collecting biopsies in clinical trials and the
variability in susceptibility of female genital tract tissue to HIV
renders this a difficult strategy. An alternative approach is to
measure the anti-HIV activity in CVL, which reflects the
biological activity of TFV as well as the endogenous antimicrobial
activity of female genital tract secretions. Extracellular drug, which
may correlate with intracellular concentrations, also could provide
a reservoir to protect immune cells in tissue and those that are
recruited into the genital tract that may play a critical role in the
expansion of the small founder population of infected cells [15].
We also expanded safety studies of TFV by examining the
impact of 14 daily vaginal applications of 1% TFV gel on
endogenous antimicrobial activity and soluble mediators of
mucosal defense. Female genital tract secretions provide endog-
enous activity against viral (HIV and HSV) and bacterial
(Escherichia coli, Group B streptococcus and Staphylococcus aureus)
pathogens [2,16,17,18,19,20,21]. This endogenous antimicrobial
activity may serve as a biomarker of a healthy genital tract
mucosal environment and could be developed as a bioassay to
evaluate microbicide safety [2]. Microbicides that trigger a loss in
endogenous antimicrobial activity could facilitate HIV infection or
HSV replication within the genital tract. Additionally, an
inflammatory response to microbicides could enhance HIV
acquisition through the recruitment and activation of HIV target
cells.
Methods
Ethics Statement
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The study was conducted according to the
Declaration of Helsinki and was approved by the Albert Einstein
College of Medicine Institutional Review Board (IRB) and the
NIAID Division of AIDS Prevention Science Review Committee.
All study participants provided written informed consent.
Participants
Thirty healthy women between the ages of 18 and 50 years were
recruited from the New York metropolitan area between February
2008 and October 2009. Inclusion criteria included regular
menstrual cycles and willingness to abstain from sex for duration
of the study. Participants were excluded for pregnancy, breastfeed-
ing, menopause, HIV, genitourinary infection, vaginitis, inter-
menstrual bleeding, abnormal Pap test, hepatitis B infection,
abnormal renal or liver function, use of hormonal contraception
during the study or in previous two months, and oral antibiotic use
during the study period.
At screening, participants had urine collected for microscopy
and culture and gynecological examination for detection of
bacterial vaginosis, Trichomonas vaginalis, Candida species, and
semen using an antibody immunoassay that detects p30, a
glycoprotein produced by the prostate (Abacus Diagnostics, West
Hills, CA). Vaginal pH was measured from a swab of the lateral
vaginal wall (Whatman pH paper, pH 3.8–5.5). CVL was
performed by washing the cervix and posterior fornix with
10 ml of normal saline (pH,5.5). A Pap test was collected, and the
presence of Neisseria gonorrhoeae and Chlamydia trachomatis infection
was determined by nucleic acid amplification testing of endocer-
vical swabs (Gen-Probe, Inc., San Diego, CA). Blood was collected
for HIV ELISA, syphilis (rapid plasma reagin test), pregnancy,
serotype specific antibodies for HSV-1 and HSV-2 (HerpeSelect,
Focus Diagnostics, Cypress, CA), hepatitis B serologies, kidney and
liver function tests.
The enrollment visit (Day 0) was completed within 30 days of
screening and 2–6 days after cessation of menstrual bleeding to
allow ample days for dosing prior to the anticipated onset of
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Candida species, pH and semen detection were repeated, and CVL
was performed. Eligible participants were then randomized 1:1 in
a double-blind fashion to receive 1% TFV or placebo gel; the
randomization was computer generated by the pharmacist. The
first dose of TFV or placebo gel was administered intravaginally by
a study clinician. Participants were instructed to apply a dose once
daily, preferably at bedtime. The participants were provided with
a diary to record usage and symptoms.
Subsequent study visits were conducted on Day 3 (range 2–4), 7
(range 5–9), 14 (range 12–15) and 21 (range 16–21). Speculum
exam, wet mount microscopy, semen test, CVL and blood
collection were performed at each visit. At each visit, used and
unused applicators were counted. Adverse event data were
collected at each study visit and graded according to the NIH
Division of AIDS Table for Grading the Severity of Adverse
Events [22]. Blood was collected for measurement of TFV-DP on
Days 3, 7, 14 and 21.
Study drugs
TFV is a clear, viscous gel containing 1% (w/w) TFV
formulated in purified water with edetate disodium, citric acid,
glycerin, methylparaben, propylparaben, and hydroxyethylcellu-
lose, with pH adjusted to 4–5. The gel is applied with a single
polyethylene or polypropylene applicator capable of administering
a 4 g (equal to 4 ml) dose of gel. The placebo is identical to TFV
gel without the TFV component. TFV and placebo gel and low-
density polyethylene applicators were provided by Gilead
Sciences, Inc. (Foster City, CA). Additional TFV and placebo
gel and polypropylene applicators were provided by Contraceptive
Research and Development Program (CONRAD) (Arlington,
VA).
CVL samples
CVL specimens were transported to the laboratory on ice and
were clarified by centrifugation at 700 g for 10 minutes at 4uC.
Supernatants were divided into aliquots and stored at 280uC. The
protein concentration (Pierce Micro BCA) and pH (ColorpHast,
pH 2–9, EMD Chemicals) of CVL samples were determined.
Peripheral blood mononuclear cells (PBMC)
Blood was collected in cell preparation tubes containing sodium
citrate (Becton, Dickinson and Company, Franklin Lakes, NJ) and
plasma was separated by centrifugation at 1500 g for 20 minutes
at 4uC. Normal saline was added to bring the total volume to
30 ml. A 0.5 ml aliquot was removed for cell counting. The cells
were pelleted by centrifugation for 15 minutes at 400 g. The
supernatants were aspirated and 1 ml of ice cold 70% methanol
solution was added to the PBMC pellet. The samples were stored
at 270uC.
Antimicrobial activity of CVL
For anti-HIV activity, TZM-bl cells were cultured in 96 well
dishes overnight. The cells were infected with HIV-1BaL
(approximately 10
3 TCID50) mixed 1:1 with CVL or control
buffer (normal saline containing 200 mg/ml bovine serum
albumin). After 48-hour incubation at 37uC, the inoculum was
removed by washing, cells were lysed with addition of luciferase
cell culture lysis reagent (Promega) and the plates were stored at -
80uC until assessed for luciferase activity, which was measured in
relative light units (RLU). Mock infected cells served as a negative
control. In select experiments, TZM-bl cells were treated with Day
7 CVL samples from the TFV or placebo group and challenged
with HIV-1BaL mixed with medium alone or with medium
containing 25% pooled whole human semen (Lee Biosolutions,
Inc.; St Louis, MO). TZM-bl inhibition was measured as mean
percent reduction compared to control. All samples were tested in
triplicate in at least two independent experiments.
The effect of CVL on E. coli was assayed as previously described
[16]. CVL or control genital tract buffer (GTB; 20 mmol/L
potassium phosphate, 60 mmol/L sodium chloride, 0.2 mg/ml
albumin, pH 4.5) was mixed with 6610
9 colony-forming units
(CFU)/ml of E. coli and incubated at 37uC for two hours. The
mixtures were then diluted 1000-fold in GTB mixed with overlay
medium and plated in duplicate on agar enriched with trypticase
soy broth (TSB). Colonies were counted using ImageQuant TL
v2005 after an overnight incubation at 37uC. All samples were
tested in duplicate and the percentage inhibition determined
relative to the colonies formed on control plates (800–1000 cfu).
For anti-HSV activity, Vero (monkey kidney epithelial) cells were
infected with HSV-2(G) mixed 1:1 with each CVL or control
buffer. After incubation at 37uC for one hour, the cells were
washed and overlaid with methyl cellulose. Plaques were counted
after 48 hours by immunoassay [4,21,23]. All samples were tested
in duplicate in two independent experiments.
Measurement of TFV in CVL and intracellular
phosphorylated TFV in PBMC
TFV and TFV-DP concentrations were determined by
validated LC-MS/MS assays. TFV was extracted from CVL via
protein precipitation with methanol followed by solid phase
extraction using HLB oasis cartridges to remove excess inorganic
salts. Chromatographic separation was achieved using a gradient
elution with a Zorbax Eclipse XDB-C18 column, subjected to
positive electrospray ionization (ESI) and detected via multiple
reaction monitoring (MRM) using a HPLC/MS/MS system
(Waters Acquity HPLC, Applied Biosystem API4000 mass
spectrometer). Calibration standards ranged from 5–1000 ng/ml
with an inter- and intra-day precision and accuracy of #6.7% with
an r
2 value of 0.997360.0023.
TFV-DP was extracted and isolated from PBMC using a single
solid phase exchange cartridge as previously described [24]. TFV-
DP was hydrolyzed to TFV and injected into the reverse phase
UPLC/MS-MS system (Waters Acquity UPLC, Applied Biosys-
tem API5000 mass spectrometer) using ESI with detection via
negative ion MRM. The assay is linear over the range of 50.0–
1,500 fmol TFV-DP/sample with a correlation coefficient (r
2)o f
0.9966. The inter- and intra-precision ranged from 1.65–13.30%,
and the accuracy was -6.68–8.67%. The recovery was $90%.
Measurement of immune mediators
Interleukin (IL)-1a, IL-1b, IL-6, IL-8, interferon (IFN)-c, IFN-
a2, IL-1ra (IL-1 receptor antagonist), macrophage inflammatory
protein (MIP)-1a, MIP-1b, and RANTES (regulated upon
activation, normal T-cell expressed and secreted) were quantified
in each CVL sample using a multiplex proteome array with beads
from Chemicon International (Billerica, MA), measured using
Luminex
100 (Austin, TX) and analyzed using StarStation (Applied
Cytometry Systems, Sacramento, CA). The levels of all other
mediators were determined using commercial ELISA kits: MIP-3a
(R & D Systems, Minneapolis, MN), secretory leukocyte protease
inhibitor (SLPI) (R & D Systems), lactoferrin (Calbiochem, San
Diego, CA), human neutrophil peptides 1-3 (HNP1-3) (HyCult
Biotechnology, Uden, The Netherlands), IgG and IgA (Cygnus
Technologies, Southport, NC) and lysozyme (Alpco Diagnostics,
Salem NH).
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Each participant received 16 pre-filled individually packaged
applicators of TFV or placebo gel and was asked to return used
and unused applicators at each study visit. Drug was dispensed
from the returned unused applicators ex vivo, and the applicators
were then batched and stained with 0.05% FD&C Blue #1
granular food dye (Prime Ingredients INC, Saddlebrook, NJ) to
detect whether the applicators had been inserted vaginally [25,26].
Applicators inserted by study staff and unused applicators
dispensed ex vivo by staff were included as positive and negative
controls, respectively. Two independent observers scored the
applicators as exposed or unexposed to vaginal mucus, and results
were compared to subjects’ self reports.
Study outcomes and statistical analysis
The primary objective of this study was to assess the mucosal
response to repeated applications of 1% TFV or matched placebo
gel by measuring biomarkers of mucosal immunity in CVL.
Secondary objectives were to assess the antimicrobial activity of
CVL, to correlate this activity with the concentration of drug in
CVL and with levels of antimicrobial proteins, and to evaluate
candidate biomarkers of adherence.
Descriptive statistics (mean, standard error (SE), minimum,
maximum) were computed, and graphical representations were
generated using the average marker value (61 SE) for each day
and group. Concentrations of immune mediators were log-
transformed, where appropriate. Random effects linear regression
was used to estimate the effect of treatment and time on average
post-baseline marker levels, while also adjusting for baseline (Day
0) levels. Treatment arm was represented in the model as an
indicator variable (X=1 if assigned to TFV arm, 0 if placebo),
baseline marker level was represented as a continuous value, and
day of treatment (day=3, 7, 14, or 21) was represented as a
categorical variable. The interaction between treatment and day
was also examined for each marker. Subjects contributed up to
four follow-up measurements (days 3,7,14, and 21) for analysis,
therefore a subject-specific random intercept was used to account
for the expected positive correlation between marker levels from
the same individual. Parameter estimates and standard errors were
based on maximum likelihood estimates. P-values for the fixed
effects of treatment and day were generated based on the t-statistic
and Kenward-Roger adjusted degrees of freedom. Type 3 tests for
the overall effect of day (categorical) were computed as a summary
and p-values presented. The a priori primary markers of interest in
this study (anti-HIV and anti-HSV activity) were evaluated with
no adjustment of the p-value for multiple testing. However for the
analysis of all 22 candidate biomarkers of safety, we set a more
conservative alpha level of 0.01 to identify statistically significant
treatment effects and to account for multiple hypothesis testing. In
the case of safety biomarkers, we wanted to retain the null
hypotheses, therefore the use of a more stringent Bonferroni p-
value adjustment threshold (p-value ,0.0023) for testing 22
independent immune markers would likely be non-conservative,
resulting in false negatives.
Spearman’s correlation coefficients (SCC) were calculated to
determine if antimicrobial activity correlated with concentrations
of immune mediators and to determine if anti-HIV activity in
CVL samples correlated with CVL TFV levels. Pharmacodynamic
analysis of TFV concentration association with percentage HIV
inhibition was performed after probit transformation of percent-
ages. The data were fit to various models including terms for
maximum effect (Emax), baseline effect (E0), TFV concentration at
half-maximal effect (EC50), and gamma exponent (Hill coefficient)
and evaluated for goodness-of-fit. All statistical analyses were
performed with GraphPad Prism (version 4; GraphPad Software,
La Jolla, CA) and with SAS (version 9.2; SAS Institute Inc., Cary,
NC).
Sample size
A total sample size of 24 (12 subjects in each arm) was selected a
priori to allow 80% power to detect of a 0.55 log unit difference in
immune mediator concentrations between groups, assuming a
standard deviation of ,0.5 log units for most mediators [2] and a
5% alpha value. To supplement loss to follow-up, we committed to
enrolling 30 participants.
Results
Study subjects
Fifty-six women were assessed for eligibility, and 30 were
enrolled (Fig. 1). The majority of exclusions were due to an
abnormal Pap test (n=8) or failure to return for enrollment (n=6).
Twenty-six participants completed the trial, including 12 in the
TFV and 14 in the placebo group, with the remaining women
(non-completers) contributing at least one observation to the
analysis, for a total analysis set consisting of 30 subjects and 108
valid observations for most markers. One participant in the TFV
group was excluded shortly after the enrollment visit because she
required oral antibiotics for a hand injury. Two participants in the
TFV group requested early termination after the Day 3 visit, one
for personal reasons and the other because of discomfort with
blood draws. One participant in the placebo group was lost to
follow-up after the Day 7 visit. Demographic data are shown in
Table 1. Women in the TFV group had more lifetime sex partners
and reported more anal sex than women who received placebo.
Tolerance of TFV gel
Thirteen of 30 (43%) women reported 37 adverse events that
were either possibly or probably related to study product. The
most frequent were itching or burning of the vulva or vagina. All
were Grade 1 (mild) and there were no differences in adverse
events between the groups. Half of all the women reported gel
leakage. There were no significant differences in vaginal pH from
baseline within the two groups or between groups at any point in
the study. No participant who received TFV or placebo gel met
Amsel’s criteria for the diagnosis of bacterial vaginosis at any time
during the study.
Anti-HIV activity of CVL in the setting of TFV gel use
At baseline, average anti-HIV activity in CVL was 28.1610.5
(mean 6 SE) and 32.267.2 in the TFV and placebo group,
respectively, indicating the low but variable endogenous activity of
genital tract secretions [2,4,19,20,27]. CVL from TFV-treated
subjects exhibited consistently higher anti-HIV activity than CVL
from placebo-treated subjects, adjusting for time and baseline
levels (p,0.001) (Fig. 2). No statistically significant interaction
effect between treatment and day was observed. CVL collected
from TFV-treated subjects on Day 21 (range 36–181 hours post
last gel application) was found to have significantly less anti-HIV
activity than on Day 7 (p,0.005).
Anti-HIV activity in CVL containing TFV when virus is
introduced in semen
Cells were treated with CVL obtained on Day 7 from women in
the TFV or placebo group and were then challenged with HIV
diluted in 25% pooled human semen or medium. Samples with
higher endogenous activity were selected from the placebo cohort
Biomarkers of TFV Gel Pharmacodynamics and Safety
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activity. The anti-HIV activity in CVL from TFV-treated subjects
persisted when virus was introduced in semen. However anti-HIV
activity in CVL from placebo subjects was lost or significantly
reduced (Fig. 3). Similarly, the endogenous anti-HIV activity in
CVL obtained from either group at baseline (Day 0) was also lost
when virus was introduced in semen (not shown).
Pharmacokinetics
TFV was detected in CVL supernatants on Days 3, 7, 14 and 21
(Fig. 4, upper panel). None of the CVL samples from women at
Day 0 or from women in the placebo group had detectable TFV
levels. TFV concentrations at Day 21 (range 36–181 hours post
last gel application) were significantly lower than the concentra-
tions detected on Day 7 (p=0.02) and correlated inversely and
significantly with the time post gel application (r=20.59,
p=0.04). The finding that TFV persisted up to 181 hours post-
gel application could reflect the prolonged half-life of extracellular
drug in the vaginal lumen and/or transport of dephosphorylated
drug from intracellular stores (where the phosphorylated moiety is
known to have a prolonged half-life) back into the extracellular
space of the cervicovaginal tissue or lumen. One subject had TFV-
DP detectable in PBMC isolated from the blood, which were 1.94,
1.83 and 2.63 fmol/10
6 cells on Days 7, 14 and 21, respectively.
For context, under steady-state conditions after chronic, daily oral
dosing of 300 mg of tenofovir disoproxil fumarate (TDF), median
trough (C24) concentrations of intracellular TFV-DP concentra-
tions in PBMCs have been variably reported as 87 fmol/10
6 cells
in patients on triple nucleotide regimens [28], 108–247 fmol/10
6
cells in patients on protease inhibitor- containing regimens [29]
and 50 fmol/10
6 cells in healthy women in an oral pre-exposure
prophylaxis trial (C. Hendrix, unpublished data).
CVL TFV concentrations correlated positively and significantly
with the anti-HIV activity (r=0.6, p,0.001) (Fig. 4, lower panel).
The data best fit a sigmoid Emax pharmacodynamic model
including terms for baseline effect, as baseline percentage HIV
inhibition was not 0 (reflecting endogenous activity of genital tract
secretions). Parameter estimates (95% multivariate confidence
intervals) were as follows: Emax 97 (62–100), E0 5 (0–57), EC50
496 ng/mL (-775,1769). Additional terms for sigmoidicity did not
improve the model. 33 of 34 (97%) CVL specimens with a TFV
level .1,000 ng/ml were associated with . 69% HIV inhibition,
and 30 of 34 (88%) were associated with .80% inhibition.
Furthermore TFV concentrations greater than 6,000 ng/mL were
associated with 88 to 100% HIV inhibition. These findings are
consistent with in vitro studies in which the concentration of TFV
that inhibits HIV infection of TZM-bl cells by 90% is 5–10 mg/ml
(data not shown). However, there were a few outliers. CVL from
one subject exhibited a TFV concentration of 3,990.8 ng/ml but
no anti-HIV activity was detected. Conversely, 3 subjects with
.90% HIV inhibition had low CVL TFV concentrations (12.44–
114.5 ng/ml).
Figure 1. Trial profile.
doi:10.1371/journal.pone.0016475.g001
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Applicator staining has been proposed as a potential objective
measure of adherence to distinguish vaginally-applied from unused
applicators. However, prior studies suggest that the sensitivity and
specificity of this approach varies with the type of applicator
[25,26,30,31]. To further evaluate the potential utility of
applicator staining as a biomarker of adherence, participants were
asked to return used and unused applicators at each study visit.
The returned applicators were batched and stained within four
months along with positive (applicators inserted by study staff) and
negative (unused applicators that had been dispensed ex vivo)
controls. The first eight participants in this study inserted
polyethylene and the remaining 22 inserted polypropylene
applicators. The staining procedure was limited to polypropylene
applicators, which are being used in ongoing TFV clinical trials.
A total of 349 of 352 (99%) polypropylene applicators were
returned, including 289 that participants reported had been
intravaginally applied and 60 unopened pre-filled applicators.
Verbal report and diary review matched 100% for drug
application. Both observers correctly identified all of the
applicators inserted by study staff (22/22) as positive (positive
predictive value 100%) and scored 90% and 92%, respectively,
of the returned applicators that were reported to have been
used as positive. However, the two observers identified only 6/
22 (27%) and 12/22 (54%) of the negative controls as negative
and 49/60 (82%) and 41/60 (68%), respectively, of the
returned unused applicators as negative (Table 2). No
difference in the ability to detect intravaginal insertion of
applicators was noted between subjects who had received TFV
or placebo gel.
Table 1. Demographic data of recipients of 1% tenofovir and placebo gel.
Tenofovir Gel
N=15
Placebo Gel
N=15 p value
Age (years)
Mean 6 standard deviation (SD)
32.4766.84 28.3367.02 0.11
Race (number, %)
Black
White
Other
6 (40%)
5 (33%)
4 (27%)
5 (33%)
7 (47%)
3 (20%)
0.75
Ethnicity (number, %)
Hispanic
Non-Hispanic
3 (20%)
12 (80%)
3 (20%)
12 (80%)
1.0
Level of Education (number, %)
High school/General education diploma
Some college
College
Graduate/Professional degree
Some post-college
3 (20%)
6 (40%)
3 (20%)
2 (13%)
1 (7%)
1 (7%)
6 (40%)
4 (26.5%)
4 (26.5%)
0
0.59
Number lifetime sex partners
Median (range)
7 (1–50) 4 (0–15) 0.03
Reported history of anal sex (number, %) 8 (53%) 1 (7%) 0.01
Current cigarette smoker (number %) 3 (20%) 1 (7%) 0.59
Tampon use (number, %) 9 (60%) 14 (93%) 0.08
History of douching (number, %) 4 (26.5%) 2 (13%) 0.65
Mean duration of menstrual cycle (days 6 SD) 26.861.57 28.461.12 0.003
Mean duration of menses (days 6 SD) 4.560.99 5.0761.28 0.16
Current contraceptive method (number)
*
Male condoms
Female condoms
Tubal ligation
Spermicide
Withdrawal
Natural family planning
9
1
0
1
1
1
9
1
1
0
2
1
0.81
Prior history of vaginitis (number)
Candida vaginitis
Bacterial vaginosis
10
3
7
2
0.42
Prior history of STI (number)
Trichomonas
Chlamydia
Gonorrhea
Genital warts
1
2
1
1
1
1
0
0
0.39
HSV seropositivity (number, %)
HSV-1 seropositive
HSV-2 seropositive
11 (73%)
4 (26.5%)
6 (40%)
2 (13%)
0.14
0.65
*More than 1 method may have been reported.
doi:10.1371/journal.pone.0016475.t001
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Prior studies demonstrate that genital tract secretions collected
by lavage or swab inhibit E. coli and HSV-2 and that this activity
may provide a surrogate marker of an intact soluble mucosal
immune environment [2,16,18,21]. To determine whether
repeated application of TFV or placebo gel impacted this host
defense, CVL were assayed for anti-E. coli and anti-HSV activity
as well as concentrations of antimicrobial mediators. Mean
percent inhibition (61 SE) of E. coli was 67.565.1 and
66.365.6 per ml of CVL at enrollment (Day 0) in the TFV and
placebo groups, respectively. There was no loss in anti-E. coli
activity relative to Day 0 in either group (Fig. 5, upper panel).
Consistent with prior studies, endogenous anti-HSV activity was
variable [21]. The mean percent inhibition (61 SE) of HSV-2
plaque formation was 42.868.3 and 38.866.8 per ml of CVL on
Day 0 in the TFV and placebo groups, respectively. There were
no statistically significant differences in anti-HSV activity between
the TFV and placebo groups (Fig. 5, lower panel). These findings,
which contrast with the unanticipated observation in the
CAPRISA 004 trial that TFV gel provided 51% protection
against HSV-2, may reflect the relatively high concentrations of
TFV needed to block HSV replication. In ongoing studies, we
found that TFV concentrations ,100 mg/ml had little or no anti-
HSV activity in parallel plaque assays. The mean concentration of
TFV in the CVL samples was 13.562.8 mg/ml (mean 6 SE)
(maximum concentration 93.7 mg/ml).
In evaluating levels of soluble immune mediators, cytokines, and
chemokines (Table 3) for both groups, we found significant
variation in levels at each visit and changes in log marker levels
across visits. There was no statistically significant group effect
observed for any soluble mediator, using a threshold of p-value
,0.01.
We found a modestly positive but significant correlation
between anti-HSV and anti-E. coli activity in CVL samples
(r=0.25, p=0.003), suggesting that redundant pathways contrib-
ute to innate defense against various pathogens. The anti-E. coli
activity correlated modestly with lysozyme (r=0.24, p=0.004)
and total protein (r=0.28, p,0.001). The anti-HSV activity
correlated positively and significantly with the concentrations of
HNP1-3 (r=0.48, p,0.001), lysozyme (r=0.47, p=,0.001) and
IgA (r=0.32, p,0.001), which is consistent with prior studies
[18,21]. Moreover, anti-HSV activity correlated with IL-8
(r=0.26, p=0.002), and concentrations of HNP1-3 correlated
positively and significantly with IL-8 (r=0.52, p,0.001), which is
consistent with the role this chemokine plays in recruiting
neutrophils, which are the primary source of HNP1-3.
Discussion
The recent observation that coitally-related TFV gel dosing
provides partial protection against HIV acquisition is the first
indication that vaginal microbicides have the potential to stem
the HIV epidemic. These encouraging findings also underscore
the need for more predictive biomarkers of microbicide PD and
safety for future clinical trials, which will likely become more
complex as we strive to achieve higher levels of protection with
alternative dosing, varying formulations, and combinations of
drugs. The current study indicates that TFV gel does not
interfere with soluble mucosal immunity, a biomarker of safety,
and that measurement of anti-HIV activity and drug levels in
CVL may provide simple and inexpensive assays of PD (drug
activity) and PK (drug distribution and clearance) near or at the
site of drug action. Measurements of PK and PD in CVL are
directly applicable to drugs that act luminally or for products in
which the intracellular and extracellular drug pools are in
equilibrium. Importantly, results obtained in this study suggest
that this approach may also provide insight into drugs such as
TFV, which is only active after intracellular modifications and for
which the low permeability of the intracellularly charged
nucleotide leads to accumulation of phosphorylated drug with a
long half-life in the intracellular pool.
The anti-HIV activity in CVL samples collected after gel use
provides a direct measurement of the bioactivity of extracellular
drug, which may serve as a reservoir to protect newly recruited
immune cells. The importance of this is highlighted by non-human
primate studies, which illustrate the central role of these cells in the
establishment of infection. Virus crosses the mucosal epithelial
barrier within hours to establish a small founder population of
infected cells [15]. This founder population then undergoes local
expansion during the first week of infection to generate sufficient
virus and infected cells to disseminate and establish a systemic
infection. Because the number of immune targets within the
Figure 2. Increased anti-HIV activity in CVL from women who
applied tenofovir gel. Results are presented as mean percentage
inhibition 6 SE obtained from two independent experiments, each
conducted in triplicate.
doi:10.1371/journal.pone.0016475.g002
Figure 3. Anti-HIV activity of TFV persists if virus is introduced
in semen. TZM-bl cells were treated with CVL collected from four
subjects in the TFV group (T) and 4 from the placebo group (P) on Day 7
and then challenged with HIV-1BaL diluted in medium alone or in
medium containing 25% pooled whole human semen. Results are
presented as mean percentage inhibition 6 SE obtained from two or
three independent experiments, each conducted in triplicate.
doi:10.1371/journal.pone.0016475.g003
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recruitment and activation of additional target cells is critical to
the establishment of infection. Thus, it is important that a
sufficient reservoir of extracellular drug be available to block
infection of recruited target cells.
The current study did not include biopsy sampling, but PK data
obtained in recently completed clinical studies should provide data
to determine whether concentrations of drug in intracellular tissue
and extracellular compartments correlate. If this proves true, then
CVL sampling could be added to clinical trials and may provide a
more realistic and reproducible approach than biopsies for
measuring PK and PD in clinical trials. These highly feasible
assays could also provide an objective measure of adherence to gel
product. The need for better markers of adherence is underscored
by the suboptimal results and relatively high false-positive rate for
polypropylene applicator staining observed in this study and by the
low sensitivity of this technique reported in a previous study [26].
The high degree of interobserver variability suggests that staining
of polypropylene applicators is not an effective method of
determining compliance among participants enrolled in microbi-
cide trials.
Figure 4. CVL tenofovir levels correlate with anti-HIV activity in
CVL. The concentration of TFV was determined in CVL samples
collected on Days 3, 7, 14 and 21 (upper panel). Each data point
represents the TFV level obtained from a single CVL sample, with the
median for each group represented by a horizontal line. CVL TFV
concentrations correlated positively and significantly with percentage
inhibition of HIV (lower panel).
doi:10.1371/journal.pone.0016475.g004
Table 2. Blue Dye staining of polypropylene applicators.
Applicator Staining N
Observer 1
No. (%)
Observer 2
No. (%)
Positive Controls 22 22 (100) 22 (100)
Negative Controls 22 6 (27) 12 (54)
Returned applicators
reported used
289 261 (90) 266 (92)
Returned unopened
applicators reported
unused
60 49 (82) 41 (68)
Two observers were asked to differentiate applicators that were intravaginally
inserted from applicators that were not intravaginally inserted. Applicators
inserted by study staff and unused applicators that were dispensed ex vivo were
included as positive and negative controls, respectively.
doi:10.1371/journal.pone.0016475.t002
Figure 5. Endogenous anti-E. coli and anti-HSV activity
following vaginal application of TFV and placebo gel. The
percentage inhibition of E. coli was determined relative to colonies
formed on control plates treated with GTB (upper panel). Vero cells
were infected with HSV-2(G) mixed 1:1 with CVL or control buffer (lower
panel). Results are presented as mean percentage inhibition of cfu or
plaque forming units (pfu) 6 SE. All samples were tested in duplicate in
two independent experiments.
doi:10.1371/journal.pone.0016475.g005
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observation that TFV gel provided 51% protection against HSV-2
(Q. Abdool Karim, unpublished data). Prior in vitro assays
indicated that TFV inhibits HSV only at relatively high
concentrations with IC50 .100 mg/ml (B. Herold, unpublished
data), which is consistent with the absence of any increase in the
anti-HSV activity of CVL obtained from women in the TFV
group when compared to the women in the placebo group. The
concentrations of intracellular TFV-DP achieved in CAPRISA
004, however, may have been of sufficient magnitude to protect
against HSV-2 infection.
The persistence of drug and higher levels of anti-HIV activity in
CVL obtained at the last study visit (36–181 hours post last gel
application) may reflect the prolonged half-life of extracellular
TFV within the vaginal lumen or release of dephosphorylated
drug from intracellular stores (either within cervicovaginal tissue or
within the lumen) back into the extracellular luminal space, either
via tissue and then into the lumen or into the lumen directly from
luminal cells. Both epithelial and immune cells efficiently
phosphorylate TFV, and a half-life of several days has been
demonstrated in vitro in both cell types [13]. The extent to which
TFV-DP is dephosphorylated has not been well established.
However, the observation of increased anti-HIV activity in these
samples suggests that even in the setting of intermittent gel
application, there may be sufficient bioactive drug within the
genital tract to provide some protection against HIV infection.
The extent of antiviral activity needed for protection, however, is
not known.
Additional limitations of the current study are that it was of
short duration and was conducted among sexually abstinent
women. Sexual activity may alter the PK and PD of candidate
microbicides. In the only postcoital study of microbicide PK and
PD, we found that less PRO 2000 was recovered in CVL after sex,
which in combination with diminished PRO 2000 activity in the
presence of seminal plasma proteins, may have contributed to the
loss in antiviral activity [4]. While semen does not interfere with
the antiviral activity of TFV in cell culture (Fig. 3), sexual activity
may impact the PK and PD, depending on the timing of gel
application and frequency of sex. For example, if gel is applied
shortly prior to intercourse, a substantial proportion may be lost
due to leakage before or during sex. This may have little impact in
the context of consistent daily gel application, but could result in
insufficient drug in the setting of intermittent use and frequent
sexual exposure. In addition, given that the volume of semen could
be as large as the volume of gel within the vagina, the addition of
semen may have a substantial dilutional effect on TFV
concentrations within the lumen, even if there is no effect of
semen on TFV activity, per se. Thus, additional postcoital
sampling studies would provide important insights into optimal
dosing frequency and may support the postcoital dosing design
used in the CAPRISA 004 trial.
It is noteworthy that while the anti-HIV activity in CVL
obtained from women in the TFV group persisted when virus was
introduced in human semen, the endogenous anti-HIV activity
observed in women who received placebo was significantly
reduced. Similar results were observed with postcoital CVL
obtained in the absence of PRO 2000 gel application [4]. Possibly,
specific enzymes and/or proteases or the high pH of semen
inactivate, degrade, or interfere with protective immune mediators
present in the female genital secretions resulting in a reduction in
endogenous antimicrobial activity.
In addition to identifying potential biomarkers of microbicide
PD and adherence, the current study also suggests that
measurements of endogenous antimicrobial activity and immune
mediators in CVL may provide additional insights into microbi-
cide safety. We observed no increase in proinflammatory cytokines
or chemokines or loss in protective immune mediators or
endogenous antimicrobial activity. Although our relatively small
sample size may limit our ability to detect subtle changes in
concentrations of immune mediators, our results are consistent
with the safety of TFV gel demonstrated in the CAPRISA 004
study. While chemokines may block viral entry by binding to
CCR5 and contribute to endogenous anti-HIV activity, increases
in their expression may paradoxically facilitate infection by
increasing target cell availability. This notion is supported by
primate studies in which SIV induces the release of MIP-3a in the
epithelium, which triggers the release of MIP-1b by plasmacytoid
dendritic cells, resulting in subsequent recruitment of CD4+T cells
Table 3. Summary of Day 0 concentrations of soluble
immune mediators and pH and comparison of changes in
levels between TFV and placebo groups.
Day 0
Tenofovir Day 0 placebo
Group
effect
P
value
Median (IQR)
Protein (mg/ml) 230 (150–406) 193 (125–404) 20.25 0.05
Lysozyme (ng/ml) 95 (74–330) 105 (79–654) 20.18 0.32
Lactoferrin (ng/ml) 378 (136–609) 526 (82–825) 20.41 0.09
SLPI (ng/ml) 250 (122–337) 124 (34–320) 20.57 0.04
IgA (mg/ml) 2 (0.4–3) 1 (0.4–2) 20.15 0.51
IgG (mg/ml) 16 (7–34) 12 (5–33) 20.28 0.12
HNP1-3 (ng/ml) 29 (8–346) 39 (10–576) 0.21 0.64
IFN-a2 (pg/ml) 4 (2–8) 4 (2–8) 20.01 0.97
IFN-c (pg/ml) 1 (0.6–1) 1 (0.1–3) 20.25 0.28
IL-1a (pg/ml) 28 (11–77) 49 (22–95) 20.62 0.02
IL-1b (pg/ml) 2 (1–4) 3 (0.1–15) 20.16 0.66
IL-1ra (ng/ml) 8 (6–12) 7 (4–10) 20.25 0.01
IL-6 (pg/ml) 12 (3–33) 14 (2–19) 20.22 0.56
IL-8 (pg/ml) 153 (73–2760) 190 (90–869) 20.64 0.03
MIP-1a (pg/ml) 9 (3–14) 8 (5–18) 0.48 0.06
MIP-1b (pg/ml) 5 (2–22) 11 (4–20) 0.36 0.22
MIP-3a (pg/ml) 54 (4–151) 19 (12–77) 20.86 0.16
RANTES (pg/ml) 3 (2–5) 3 (2–5) 0.18 0.55
Estradiol (pg/ml) 86 (38–120) 54 (36–110) 16.75 0.45
Progesterone (ng/
ml)
0.3 (0.2–0.5) 0.2 (0.2–0.3) 0.77 0.54
Mean (SD)
Vaginal pH 4.63 (0.5) 4.66 (0.3) 0.14 0.09
CVL pH 4.5 (0.3) 4.59 (0.3) 0.003 0.89
IQR, interquartile range; SD, standard deviation
Mediators were evaluated on Days 0, 3, 7, 14 and 21, except for MIP-3a (Days 0,
3 and 7), estradiol and progesterone (Days 0, 7 and 14). Some subjects were
missing measurements, therefore the total number of observations was lower
for these markers. 138 observations were available for all variables with the
exception of IgG (n=137), MIP-3a (n=64), estradiol (n=81), progesterone
(n=82), vaginal pH (n=137), and CVL pH (n=95). Variables were log-
transformed, with the exception of estradiol, progesterone, vaginal pH, and CVL
pH. Baseline immune mediator concentrations for both TFV and placebo
subjects reflect substantial variability within subjects. Group effect represents
the effect of TFV vs. placebo treatment on mediator levels, adjusted for study
visit day. There was no statistically significant group effect for any mediator
using a threshold of p-value ,0.01.
doi:10.1371/journal.pone.0016475.t003
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transmission [32].
In summary, this work supports the inclusion of quantified anti-
HIV activity and drug levels in CVL as biomarkers of PD and PK
and soluble mucosal immune mediators and endogenous activity
as surrogate markers of safety in early clinical studies. The anti-
HIV activity in CVL should be measured with virus introduced in
medium and in semen to ensure that the activity is preserved
under conditions that more closely simulate what happens during
transmission. Ideally, postcoital sampling should be performed as
well. Results of these relatively simple assays applied in small
clinical studies are consistent with the findings of safety and
efficacy of TFV in the CAPRISA 004 study and the finding of
safety, but lack of efficacy, in two large PRO 2000 clinical trials.
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